price month
labcorp america lh
road manag
ampl driver beyond host investor meet lh
chairman ceo dave king cfo glenn eisenberg manag
remain confid target call ep rise predic
top-line growth reflect contract shift divestitur
pama ebitda margin degrad estimate bp partial off-set
dilig cost structur initi admittedli transit year
lh view multipl avenu lt growth across diversifi platform
strong cf gener offer capit deploy flexibl particularli
relev given role lead consolid post-pama world
anticip activ beyond
clinic laboratori updat lt view major payor contract lock
lh emphas enhanc price visibl remain confid
lcd growth target jan volum line expect
pama reform oral argument expediti schedul apr
lh optimist reimburs relief decis
encouragingli follow transit year lh expect long term lcd
growth support volum greater util innov
price favor mix potenti supplement growth
diversifi custom mix scope offer posit cdd above-
market growth view rfp flow across industri robust buoy
healthi outsourc demand also note ration price
environ importantli view cdd woefulli underappreci
ascrib ev/ebitda line
lcd impli cdd multipl discount peer
rais tp greater convict lt growth
prospect visibl thereon support also sotp analysi risk
headwind govern reimburs chang
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
labcorp america lh
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
labcorp america lh
host investor meet lh chairman ceo dave king evp cfo
glenn eisenberg new vice-president ir clarissa willett thesi remain lh multipl
avenu growth across diversifi platform despit near term headwind
core lcd strong cf gener offer capit flexibl particularli relev given
role lead consolid smaller lab oper post-pama world
manag re-affirmed ep guidanc provid feb
well ahead prior estim midpoint par consensu
despit continu lab unit challeng pama contract
headwind contribut admittedli transit year
impact food solut divestitur
impact pama
contract shiftsat better end anticip impact quest
diagnost view gain volum measur basi throughout
year relat contract shift horizon lh view major
physicians/pati wish switch make chang immedi
consist experi lh becam unh exclus provid
term lh think anticip volum shift model volum
loss custom util non- busi assum
busi shift volum gain custom util lh
non-aetna busi volum loss horizon contract chang
partial off-set new access aetna importantli thu far lh experienc
volum loss better end anticip rang aetna gain line
forecast
prefer laboratori network term implement potenti
nation prefer laboratori network lh view reason disadvantag
nation laboratori provid particularli implement first full year non-
exclus contract moreov view nation prefer lab network may act
potenti tailwind major nation lab provid particularli choos
reduc size overal network reduc out-of-network lab util note
health plan lab trend remain high dd primarili predic util
out-of-network plan part network essenti unmanag lh
highlight base recent convers health plan becom increasingli
interest better manag lab cost trend
pama lh experi increment reimburs cut pama
dynam fulli detail lh anticip headwind
lcd revenu consist lower direct medicar reimburs million
well indirect impact reimburs medicaid-rel plan
labcorp america lh
referr volum lh view soft referr volum structur issu
highlight lose account note particular
geographically-bas trend instead manag believ soft referr
one-tim issu relat late flu season abnorm lower anticip
util importantli lh note referr volum grew januari expect
volum continu grow
covanc lh guidanc covanc drug develop cdd includ neg
impact fx also note lh remain track deliv
million net save covanc three-year launchpad initi
million cost synergi integr chiltern covanc
growth appear strong manag highlight revenu growth
guidanc rang larg predic bp currenc
headwind season
quarterli cadenc remind lh expect adjust ep compar
experi y/i impli lower percentag total year
adjust ep prior year predic time covanc revenu
growth ramp launchpad save throughout year impact acquisit
divestitur well impact calendar year
relat consum genet test manag attribut recent shortfal
unquantifi combin unfortun factor estimate revenu
provid lh project signific growth november/decemb
time-frame associ typic holiday sale includ black friday/cyb monday
given suppli growth project lh hire addit employe manag
anticip volum howev experi expect holiday
rush lh left strand employe associ cost without offset
importantli lh expect experi level growth
past essenti call flat segment growth yoy said lh
remain nimbl relat consum genet test busi abil
long-term growth opportun lcd
remain transit year sever simultan headwind major
contract open unitedhealthcar aetna previous exclus
contract term increment reimburs cut relat pama manag
continu view multipl growth opportun across lcd segment
relat pama continu hope relief either judici legisl
factor would support growth pricing/reimburs perspect said
lh lab industri constitu experi pama relief expect
associ reimburs pressur drive robust deal pipelin factor alreadi
experienc today drive potenti meaning inorgan growth opportun
moreov lh continu view coverag expans demograph growth driver
longer term note highlight medicaid expans meaning potenti driver
sever larg state includ north carolina texa utah idaho among
other still implement medicaid expans albeit idaho utah
vote expans voter referendum late last year also view increment
innov specif test like cancer screen well favor coverag decis
current market diagnost test could drive materi growth
longer term lh continu expect growth lcd segment support
volum growth price base mix vs unit price potenti capit deploy
labcorp america lh
supplement growth note estim acquisit could contribut lcd
specif relat lh note pama cost inflat potenti
headwind like off-set tailwind relat lap contract
chang new health plan provid win potenti fl bcb launchpad save
florida bcb opportun note lh highlight leadership chang year
fl blue potenti posit compani view plan provid may
consid open exclus contract sinc one longest
stand exclus industri fl bcb plan repres million
custom lh remain would like benefit even indirect opportun
physician send patient lab provid whether
commerci patient bcb medicare/medicaid patient may send relev
volum lh essenti enabl lh achiev greater foothold fl
medicare/medicaid market well renew contract long
ago lh highlight contract caus opt-out provis
court finish brief pama case yet oral argument
schedul april lh view expediti schedul trial typic done
case fulli brief posit impli court potenti agre
seriou issu address pama importantli lh expect hear
decis summer/fal assum delay remind septemb
 district court district columbia dismiss lawsuit brought forth
american clinic laboratori associ acla reform propos rate cut part
clinic lab fee schedul clf protect medicar act pama
court view acla testimoni rais pertin question ultim
conclud court author act matter
said manag view increas awar pama drive increment
lead nurs home focus laboratori meaning medicar exposur file
bankruptci last week provid indic potenti impact smaller
player regardless without pama relief lh view dynam drive
refer pama design bring medicar price par commerci
market counterpart howev determin proper rate collect
price data two largest nation lab labcorp quest diagnost
repres total laboratori test market moreov given two
lab typic consid low-cost provid price smaller region player
laboratori industri argu inaccur calcul commerci rate lead
far oner cut appropri
lh launch phase ii launchpad cost structur initi focus
diagnost busi unit lcd expect drive million save
within three year exp one-third year potenti opportun thereon
lh think launchpad doesnt necessarili focu intern specif cost
target rather gener digit busi streamlin process
new technolog radic transform inher creat cost save
time importantli lh view opportun drive gross margin back
histor level vs time
launchpad phase ii lh plan focu elimin manual process digit
busi use technolog improv qualiti oper servic enhanc
labcorp america lh
consum experi well bring servic closer consum exampl
aim elimin use paper paper bill also target greater
leverag certain back offic depart includ bill depart said lh
expect captur anticip cost save sg line
highlight lh channel expans push includ relationship walgreen
well recent launch pixel self-collect dtc devic date lh open
blood draw station walgreen six state goal open locat
end least station aggreg next four year
note believ lh scale stand-alone diagnost center open
draw station walgreen store also achiev better overal custom access
said lh also optimist broader driver new access pharmaci data
abil bundl servic patient well opportun relat health
well trial recruit cro busi
lh also note consum focu within diagnost center
compani implement sever innov simplifi enhanc consum
experi includ new sign-in machin center similar check
flight view well patient portal custom may easili view
result via phone tablet comput meanwhil emphas longer term growth
potenti pixel devic self-collect tool health well consum
expect expand test menu time
manag note pharma sponsor lh biggest competitor
signific amount clinic trial work still done intern continu emphas
healthi robust clinic trial outsourc demand environ continu
recent commentari smaller cro competitor weaker rfp flow tuesday
lh manag appear bullish space highlight rfp flow remain strong
broad-bas across therapeut class custom size large-pharma mid-siz
lh also highlight consist biotech fund environ particularli
role biotech chang drug develop ecosystem histor biotech
compani larg fund angel investor howev biotech essenti act
pipelin larg pharma sponsor provid meaning consist
fund remind lh also note healthi environ term ventur
capit broader biotech fund highlight strong molecul pipelin
notabl increas cancel across market
highlight covanc advantag lcd data asset
signific challeng clinic trial sponsor face patient recruit
reluct patient enrol trial due burden particip howev
manag continu highlight integr cro busi lab unit
key solut increas conveni patient lower travel burden
util network nearli labcorp patient servic center well build
walgreen presenc perform basic safeti assess function without need
visit physician
associ lab data also drive competit differenti lh driven
faster recruit perform includ increas speed enrollment/studi start-up
rel market almost nine month muscl skelet disord five
month neurolog four month oncolog moreov longer term lh expect
expand data reach walgreen relationship leverag pharmaci data alongsid
labcorp america lh
biolog diagnost data anoth competit differenti importantli lh data
asset use rfp
figur lh month trial save rel rest market
muscl skelet
rest market
lh look sever deal bolster lcd segment activ
limit note valuat disconnect larg view pama headwind
fulli bake next step pama-rel price cut lh view
experi increment opportun consist previou view note
pipelin like compris smaller strateg tuck-in acquisit
see mani larg deal million market
term dividend lh discuss implement intern howev
view compani initi dividend near term particularli covanc continu
grow healthi pace opportun remain robust driven pama
reimburs headwind across industri said lh note potenti
upsid dividend includ access new sharehold incom focus
potenti provid investor relief plan anoth large-scal acquisit
 covanc provid sens capit return sharehold
preclin busi lh remain second largest constitu preclin
market behind charl river laboratori importantli compani state
remain commit busi time said note lh
commit food busi eurofin offer acquir million
particularli scale becom increasingli import aspect clinic space
lh look potenti deal cro space highlight rich valuat
market right note premium paid richli valu busi
under-valued busi remain difficult justifi
consolid among
labcorp america lh
labcorp america lh
figur lh part analysi ccd impli valuat
sale
sale
corpor
labcorp america lh
compani mention price
labcorp america lh outperform tp
